– Company ended the quarter with $58.2 million in cash
– Driving continued progress across diversified pre-clinical and clinical development pipeline
TORONTO, ONTARIO, Aug. 03, 2022 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (Nasdaq: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the second quarter ended June 30, 2022 and recent highlights.
“Throughout the quarter, we continued to execute against our strategic priorities,” said Dr. Klaus Paulini, Chief Executive Officer of Aeterna. “As we look ahead, we are laser focused on building on the positive momentum we’ve achieved across our therapeutics, diagnostics and vaccine development pipelines, all with an eye towards generating value in the near and long term for our valued stakeholders.”
Recent Highlights
- Announced that licensing partner, Consilient Health, launched Ghryvelin™ (macimorelin) for diagnosing adult growth hormone deficiency (AGHD) in Europe;
- Achieved proof-of-concept for the treatment of neuromyelitis optica spectrum disorder (NMOSD) with AIM Biologicals program in animal experiments; and
- Entered into a research and option to license agreement with UniQuest Pty Ltd., the commercialization company of The University of Queensland (UQ), Brisbane, Australia, to advance the development of…
